Thalidomide Stimulates Splenic IgM Antibody Response and Cytotoxic T Lymphocyte Subpopulation Numbers in Female B6C3F1 Mice

Details

• Personal Author:
  Brown RD ; Germolec DR ; Karrow NA ; McCay JA ; Munson AE ; Musgrove DL ; Pettit DA ; White, Kathy L.
• Description:
  Thalidomide has been shown to have antiinflammatory and, more recently, immunomodulating properties, which are beneficial for the treatment of an ever-increasing list of immune related diseases. Although considerable knowledge regarding thalidomide's antiinflammatory properties has been acquired, relatively little is known about its immunomodulating properties in vivo. In this paper, a panel of immune assays was used to evaluate immunomodulation in female B6C3F1 mice treated intraperitoneally for 28 days with thalidomide (30, 100, or 150 mg/kg/day). Spleen antibody forming cell response was significantly enhanced by 37% in mice treated with 150 mg/kg/day, despite an 8% decrease in the percentage of Ig+ B cells. A significant stimulatory trend was observed for the cytotoxic T cell response across thalidomide treatment groups. An evaluation of the spleen leukocyte subpopulations revealed a 23% increase in the absolute number of CD8+ T cells in the 150 mg/kg treatment group and a 9 and 11% decrease in the absolute number of NK cells in both the 100 and 150 mg/kg thalidomide treatment groups, respectively. These findings demonstrate that, in addition to modulating spleen leukocyte numbers, thalidomide also stimulates murine humoral and cellular immune responses in vivo. [Description provided by NIOSH]
• Subjects:
  Animals Blood Immune System Laboratories Occupational Health Safety
• Keywords:
  Animal Studies Author Keywords: Thalidomide B6C3F1 Mice Immune System Disorders Immunomodulation In Vivo Studies Laboratory Animals Lymphocytes Stimulants
• ISSN:
  0041-008X
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  North Carolina ; OSHA Region 3 ; OSHA Region 4 ; Virginia ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  HELD - Health Effects Laboratory Division
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  237-244
• Volume:
  165
• Issue:
  3
• NIOSHTIC Number:
  nn:20020719
• Citation:
  Toxicol Appl Pharmacol 2000 Jun; 165(3):237-244
• Email:
  kwhite@hsc.vcu.edu
• Federal Fiscal Year:
  2000
• Peer Reviewed:
  True
• Source Full Name:
  Toxicology and Applied Pharmacology
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:366f56645737bc9fce71bb037b259a5fbcfb64e2ebdc05f5fec05764fe78214ee91a5448ff28eadf5f132af0de8ed43cd7330a29a4b5b2a16fd4843b02a0023e
• Download URL:
  https://stacks.cdc.gov/view/cdc/198394/cdc_198394_DS1.pdf
• File Type:
  [PDF - 100.59 KB ]